Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Since Abcam's acquisition in 2023, founder Jonathan Milner has been making waves with his investment strategy. Discover his ...

Advanced therapy medicinal products (ATMPs) are pushing the boundaries of medicine, offering hope for previously untreatable ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

The companies Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics bagged the biggest private biotech ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...

What’s behind the dip in investment in the gene therapy sector? As promising as gene therapies are, one of the main issues for investors is that these types of treatments come with a lot of risk and, ...

Exosomes are extracellular vesicles around 30 to 150 nanometers across that are generated by all cells and play crucial roles in fundamental cellular processes, such as the regeneration of damaged ...

Cystic fibrosis is a condition that causes sticky mucus to build up in the lungs and digestive system. This causes lung infections, problems with digesting food, and severe damage to several organs in ...

Adeno-associated viruses (AAVs) are promising delivery tools for gene therapy and are used in many clinical studies. However, less than ten AAV-based therapies have been approved to date. To mitigate ...